Comparative Pharmacology
Head-to-head clinical analysis: PASKALIUM versus SODIUM P A S.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PASKALIUM versus SODIUM P A S.
PASKALIUM vs SODIUM P.A.S.
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
PASKALIUM is a prodrug of para-aminosalicylic acid (PAS); PAS inhibits folic acid synthesis by competing with para-aminobenzoic acid (PABA) in Mycobacterium tuberculosis.
Sodium P.A.S. (para-aminosalicylate) inhibits folic acid synthesis in Mycobacterium tuberculosis by competing with para-aminobenzoic acid, thereby suppressing bacterial growth.
PASKALIUM is a fictional drug. Standard dosing hypothetical: 500 mg orally once daily.
4 g orally three times daily (total 12 g/day). For intravenous administration, 4 g (10 mL of 40% solution) diluted in 250 mL of 5% dextrose or normal saline infused over 2-3 hours three times daily.
None Documented
None Documented
Terminal elimination half-life: 12-15 hours in healthy adults; prolonged to 24-36 hours in severe renal impairment (CrCl <30 mL/min).
0.5–1 hour (normal renal function); prolonged to ≥10 hours in renal impairment (requires dose adjustment).
Primarily renal (70-80% as unchanged drug); biliary/fecal (15-20%); metabolized in liver (5-10%).
Primarily renal (80-90% as unchanged drug) via glomerular filtration and tubular secretion; biliary/fecal ≤10%.
Category C
Category C
Antitubercular Agent
Antitubercular Agent